# EDGAR Filing Document

**Accession Number:** 0002020932
**File Stem:** 0001104659-26-009822
**Filing Date:** 2026-2
**Character Count:** 5269
**Document Hash:** bd11dfdcdf631dac4d111c8a6ec7ba56
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-009822.hdr.sgml**: 20260203

**ACCESSION NUMBER**: 0001104659-26-009822

**CONFORMED SUBMISSION TYPE**: 8-A12B

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260203

**DATE AS OF CHANGE**: 20260203

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Agomab Therapeutics NV
- **CENTRAL INDEX KEY:** 0002020932
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** C9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-A12B
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43098
- **FILM NUMBER:** 26594561

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** POSTHOFLEI 1/6
- **CITY:** ANTWERPEN
- **PROVINCE COUNTRY:** C9
- **ZIP:** 2600
- **BUSINESS PHONE:** 32 3 302 35 30

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** POSTHOFLEI 1/6
- **CITY:** ANTWERPEN
- **PROVINCE COUNTRY:** C9
- **ZIP:** 2600

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-A**

**FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES**

**PURSUANT TO SECTION 12(b) OR (g) OF**

**THE SECURITIES EXCHANGE ACT OF 1934**

**AgomAb Therapeutics NV**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Belgium** | **Not Applicable** |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
| **Posthoflei 1/6**<br> **2600 Antwerpen, Belgium**<br> **Tel: +32 3 318 91 70** | **Not Applicable** |
| (Address of principal executive offices) | (Zip Code) |

---

Securities to be registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| **Title of each class<br> to be so registered** | **Name of exchange on which<br> each class is to be registered** |
| **American Depositary Shares, each<br> representing one common share, no nominal value<br> per share** | **The Nasdaq Stock Market LLC** |
| **Common Shares, no nominal value per share\*** | **The Nasdaq Stock Market LLC**\* |

---

\* Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC. The American Depositary Shares represent the right to receive common shares and are being registered under the Securities Act of 1933, as amended, pursuant to a separate Registration Statement on Form F-6 (File No. 333-292962). Accordingly, the American Depositary Shares are exempt from the operation of Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8 thereunder.

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), please check the following box. ⌧

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box. ◻

Securities Act registration statement number to which the form relates:

**333-292790**

Securities to be registered pursuant to Section 12(g) of the Act:

**None**

**Item 1. Description of Registrant's Securities to be Registered.**

AgomAb Therapeutics NV (the "Company") hereby incorporates by reference (a) the description of its common shares, no nominal value per share, contained under the headings "Description of share capital and articles of association," (b) the description of its American Depositary Shares, each representing one common share, no nominal value per share, contained under the heading "Description of American depositary shares," and (c) the information set forth under the heading "Material income tax considerations," in each case, in the Company's Registration Statement on Form F-1 (File No. 333-292790), as originally filed with the Securities and Exchange Commission (the "Commission") on January 16, 2026, as subsequently amended (the "Registration Statement"), and in the prospectus included in the Registration Statement to be filed separately by the Company with the Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended, which information and prospectus shall be deemed to be incorporated by reference herein.

**Item 2. Exhibits.**

Pursuant to the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be filed because no other securities of the Company are registered on The Nasdaq Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

**SIGNATURE**

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  | **AgomAb Therapeutics NV** | **AgomAb Therapeutics NV** | **AgomAb Therapeutics NV** |
| Date: February 3, 2026 | By: | /s/ Tim Knotnerus | /s/ Tim Knotnerus |
|  |  | Name: | Tim Knotnerus |
|  |  | Title: | *Chief Executive Officer and Director* |

---